Stergios A Polyzos (S A Polyzos, Jannis Kountouras)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 77

Top Venues

Alimentary pharmacology & therapeutics

Current obesity reports

Hormones (Athens, Greece)

Journal of gastroenterology and hepatology

Aristotle University of Thessaloniki

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Aristotle University of Thessaloniki Feb 06 2019

Greece

Assistant Professor :: School of Medicine

Aristotle University of Thessaloniki Feb 06 2019

Greece

Assistant Professor :: School of Medicine

Publications

Jannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, Ioannis S Papanikolaou, Christos Liatsos, Elisabeth Vardaka, Dimitrios Tzilves, Efthimia Vlachaki
Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease. Alimentary pharmacology & therapeutics 60 (4) (2024)
Ilias D Vachliotis, Athanasios D Anastasilakis, Rafailidis Vasileios, Stergios A Polyzos
Osteokines in Nonalcoholic Fatty Liver Disease. Current obesity reports (2024)
Alessandro Mantovani, Alessandro Csermely, Josh Bilson, Niccolò Borella, Scoccia Enrico, Barbara Pecoraro, Emigela Shtembari, Riccardo Morandin, Stergios A Polyzos, Luca Vittorio Valenti, Herbert Tilg, Christopher D Byrne, Giovanni Targher
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut (2024)
Evangelia S Makri, Kleo Evripidou, Stergios A Polyzos
Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis. Journal of gastroenterology and hepatology 39 (5) (2024)
Alessandro Mantovani, Alessandro Csermely, Josh Bilson, Niccolò Borella, Scoccia Enrico, Barbara Pecoraro, Emigela Shtembari, Riccardo Morandin, Stergios A Polyzos, Luca Vittorio Valenti, Herbert Tilg, Christopher D Byrne, Giovanni Targher
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut 73 (9) (2024)
Stergios A Polyzos, Giovanni Targher
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current obesity reports 13 (2) (2024)
Anastasios Semertzidis, Thomai Mouskeftara, Helen G Gika, Petros Pousinis, Kali Makedou, Antonis Goulas, Jannis Kountouras, Stergios A Polyzos
Effects of Combined Low-Dose Spironolactone Plus Vitamin E versus Vitamin E Monotherapy on Lipidomic Profile in Non-Alcoholic Fatty Liver Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Journal of clinical medicine 13 (13) (2024)
Jannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, Christos Zavos, Nikolaos Grigoriadis, Ioannis S Papanikolaou, Elisabeth Vardaka, Dimitrios Tzilves, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Maria Touloumtzi, Michael Doulberis, Apostolis Papaefthymiou
Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH. Alimentary pharmacology & therapeutics 60 (5) (2024)
Jannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, Ioannis S Papanikolaou, Christos Liatsos, Elisabeth Vardaka, Dimitrios Tzilves, Efthimia Vlachaki
Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease. Alimentary pharmacology & therapeutics (2024)
Stergios A Polyzos, Giovanni Targher
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current obesity reports 13 (2) (2024)
Chara Tsiampali, Ilias D Vachliotis, Antonis Goulas, Stergios A Polyzos
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease. Hormones (Athens, Greece) (2024)
Alessandro Mantovani, Alessandro Csermely, Josh Bilson, Niccolò Borella, Scoccia Enrico, Barbara Pecoraro, Emigela Shtembari, Riccardo Morandin, Stergios A Polyzos, Luca Vittorio Valenti, Herbert Tilg, Christopher D Byrne, Giovanni Targher
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut 73 (9) (2024)
Stergios A Polyzos, Giovanni Targher
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current obesity reports 13 (2) (2024)
Evangelia S Makri, Kleo Evripidou, Stergios A Polyzos
Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis. Journal of gastroenterology and hepatology (2024)
Stergios A Polyzos, Giovanni Targher
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current obesity reports (2024)
Stergios A Polyzos, Gema Frühbeck, Dimitrios N Kiortsis
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease. Current pharmaceutical design 29 (41) (2024)
Jannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, Ioannis S Papanikolaou, Christos Liatsos, Elisabeth Vardaka, Dimitrios Tzilves, Efthimia Vlachaki
Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease. Alimentary pharmacology & therapeutics 60 (4) (2024)
Jannis Kountouras, Stergios A Polyzos, Evangelos Kazakos, Christos Zavos, Nikolaos Grigoriadis, Ioannis S Papanikolaou, Elisabeth Vardaka, Dimitrios Tzilves, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Maria Touloumtzi, Michael Doulberis, Apostolis Papaefthymiou
Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH. Alimentary pharmacology & therapeutics (2024)
Stergios A Polyzos, Gema Frühbeck, Dimitrios N Kiortsis
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease. Current pharmaceutical design 29 (41) (2024)
Anastasios Semertzidis, Thomai Mouskeftara, Helen G Gika, Petros Pousinis, Kali Makedou, Antonis Goulas, Jannis Kountouras, Stergios A Polyzos
Effects of Combined Low-Dose Spironolactone Plus Vitamin E versus Vitamin E Monotherapy on Lipidomic Profile in Non-Alcoholic Fatty Liver Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Journal of clinical medicine 13 (13) (2024)
Stergios A Polyzos, Giovanni Targher
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease. Current obesity reports 13 (2) (2024)
Michael Doulberis, Jannis Kountouras, Thomas M Stadler, Christian Meerwein, Stergios A Polyzos, Hasan Kulaksiz, Michael H Chapman, Gerhard Rogler, Daniele Riva, Ioannis Linas, John Kavaliotis, Evangelos Kazakos, Maria Mouratidou, Christos Liatsos, Apostolis Papaefthymiou
Association between Helicobacter pylori Infection and Nasal Polyps: A Systematic Review and Meta-Analysis. Microorganisms 11 (6) (2023)
Athanasios D Anastasilakis, Polyzois Makras, Julien Paccou, Ilias Bisbinas, Stergios A Polyzos, Socrates E Papapoulos
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab. Journal of clinical medicine 12 (18) (2023)
Chara Tsiampali, Paraskevi Papaioannidou, Antonis Goulas, Stergios A Polyzos
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Expert review of clinical pharmacology (2023)
Jannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, Evangelos Kazakos, Dimitrios Tzilves, Maria Touloumtzi, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Christos Liatsos, Christos Zavos, John Kavaliotis, Hasan Kulaksiz, Michael Doulberis
Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities. Alimentary pharmacology & therapeutics 57 (10) (2023)
Jannis Kountouras, Michael Doulberis, Apostolis Papaefthymiou, Stergios A Polyzos, Christos Zavos, Evangelos Kazakos, Stergios Arapoglou, Foteini Kyrailidi, Maria C Mouratidou, Marina Kleopatra Boziki, Elisabeth Vardaka
Controlling the Impact of Helicobacter pylori -Related Hyperhomocysteinemia on Neurodegeneration. Medicina (Kaunas, Lithuania) 59 (3) (2023)
Stergios A Polyzos, Apostolis Papaefthymiou, Michael Doulberis, Jannis Kountouras
Nonalcoholic fatty liver disease test: an external validation cohort. Hormones (Athens, Greece) (2023)
Michael Doulberis, Jannis Kountouras, Thomas M Stadler, Christian Meerwein, Stergios A Polyzos, Hasan Kulaksiz, Michael H Chapman, Gerhard Rogler, Daniele Riva, Ioannis Linas, John Kavaliotis, Evangelos Kazakos, Maria Mouratidou, Christos Liatsos, Apostolis Papaefthymiou
Association between Helicobacter pylori Infection and Nasal Polyps: A Systematic Review and Meta-Analysis. Microorganisms 11 (6) (2023)
Jannis Kountouras, Michael Doulberis, Apostolis Papaefthymiou, Stergios A Polyzos, Christos Zavos, Evangelos Kazakos, Stergios Arapoglou, Foteini Kyrailidi, Maria C Mouratidou, Marina Kleopatra Boziki, Elisabeth Vardaka
Controlling the Impact of Helicobacter pylori -Related Hyperhomocysteinemia on Neurodegeneration. Medicina (Kaunas, Lithuania) 59 (3) (2023)
Polyzois Makras, Maria P Yavropoulou, Stergios A Polyzos, Socrates E Papapoulos, Danai Georgakopoulou, Athanasios Papatheodorou, Athanasios D Anastasilakis
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)
Athanasios D Anastasilakis, Stergios A Polyzos, Panagiotis A Vorkas, Athina Gkiomisi, Maria P Yavropoulou, Martina Rauner, Panagiotis Nikolakopoulos, Stergios Papachatzopoulos, Polyzois Makras, Spyridon Gerou, Lorenz C Hofbauer, Andrea Palermo, Elena Tsourdi
Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study. Journal of clinical medicine 12 (16) (2023)
Dimitrios D Raptis, Christos S Mantzoros, Stergios A Polyzos
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease. Therapeutics and clinical risk management 19 (2023)
Jannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, Evangelos Kazakos, Dimitrios Tzilves, Maria Touloumtzi, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Christos Liatsos, Christos Zavos, John Kavaliotis, Hasan Kulaksiz, Michael Doulberis
Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities. Alimentary pharmacology & therapeutics 57 (10) (2023)
Jannis Kountouras, Michael Doulberis, Apostolis Papaefthymiou, Stergios A Polyzos, Christos Zavos, Evangelos Kazakos, Stergios Arapoglou, Foteini Kyrailidi, Maria C Mouratidou, Marina Kleopatra Boziki, Elisabeth Vardaka
Controlling the Impact of Helicobacter pylori -Related Hyperhomocysteinemia on Neurodegeneration. Medicina (Kaunas, Lithuania) 59 (3) (2023)
Ilias D Vachliotis, Stergios A Polyzos
Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. Current obesity reports (2023)
Jannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, Evangelos Kazakos, Dimitrios Tzilves, Maria Touloumtzi, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Christos Liatsos, Christos Zavos, John Kavaliotis, Hasan Kulaksiz, Michael Doulberis
Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities. Alimentary pharmacology & therapeutics 57 (10) (2023)
Dimitrios D Raptis, Christos S Mantzoros, Stergios A Polyzos
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease. Therapeutics and clinical risk management 19 (2023)
Ilias D Vachliotis, Stergios A Polyzos
The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current obesity reports (2023)
Stergios A Polyzos, Gema Frühbeck, Dimitrios N Kiortsis
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease. Current pharmaceutical design (2023)
Jannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, Evangelos Kazakos, Dimitrios Tzilves, Maria Touloumtzi, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Christos Liatsos, Christos Zavos, John Kavaliotis, Hasan Kulaksiz, Michael Doulberis
Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities. Alimentary pharmacology & therapeutics 57 (10) (2023)
Ilias D Vachliotis, Ioannis Valsamidis, Stergios A Polyzos
Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. Cancers 15 (21) (2023)
Myrsini Orfanidou, Charikleia Ntenti, Kleo Evripidou, Asimina Mataftsi, Antonis Goulas, Stergios A Polyzos
Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Journal of personalized medicine 13 (7) (2023)
Jannis Kountouras, Evangelos Kazakos, Anthia Gatopoulou, Stergios A Polyzos, Maria Touloumtzi, Foteini Kyrailidi, Maria C Mouratidou, Aggeliki Stogianni, Elisabeth Vardaka
Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels. Alimentary pharmacology & therapeutics 58 (11-12) (2023)
Christina Tontikidou, Evangelia S Makri, Kleo Evripidou, Dimitrios G Goulis, Antonis Goulas, Stergios A Polyzos
Circulating adiponectin in patients with nonalcoholic fatty liver disease-related liver fibrosis: A systematic review and a meta-analysis. Journal of gastroenterology and hepatology 37 (10) (2022)
Evangelia S Makri, Eleftheria Makri, Stergios A Polyzos
Combination Therapies for Nonalcoholic Fatty Liver Disease. Journal of personalized medicine 12 (7) (2022)
Stergios A Polyzos, Irene Lambrinoudaki, Dimitrios G Goulis
Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. Hormones (Athens, Greece) 21 (3) (2022)
Ilias D Vachliotis, Athanasios D Anastasilakis, Antonis Goulas, Dimitrios G Goulis, Stergios A Polyzos
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes, obesity & metabolism 24 (9) (2022)
Apostolis Papaefthymiou, Spyros Potamianos, Antonis Goulas, Michael Doulberis, Jannis Kountouras, Stergios A Polyzos
Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's & colitis 16 (5) (2022)
Jannis Kountouras, Evangelos Kazakos, Stergios A Polyzos, Dimitrios Chatzopoulos, Maria Tzitiridou-Chatzopoulou, Michael Doulberis, Apostolis Papaefthymiou, Elisabeth Vardaka
GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection. Helicobacter 27 (3) (2022)
Stergios A Polyzos, Dimitrios G Goulis, Olga Giouleme, Georgios S Germanidis, Antonis Goulas
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Current obesity reports 11 (3) (2022)
Stergios A Polyzos, Niki Katsiki
Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. Hormones (Athens, Greece) 21 (3) (2022)
Stergios A Polyzos, Christos S Mantzoros
Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need. Current medical research and opinion 38 (6) (2022)
Jannis Kountouras, Michael Doulberis, Stergios A Polyzos, E Kazakos, E Vardaka, M Touloumtzi, A Manolakis, M Tzitiridou-Chatzopoulou, C Liatsos, E S Sotiriades, S Ntona, Apostolis Papaefthymiou
Impact of Helicobacter pylori-related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies. Journal of gastroenterology and hepatology (2021)
Stergios A Polyzos, Stergios Kechagias, Emmanuel A Tsochatzis
Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Alimentary pharmacology & therapeutics 54 (8) (2021)
Athanasios D Anastasilakis, Stergios A Polyzos, Maria P Yavropoulou, Natasha M Appelman-Dijkstra, Charikleia Ntenti, Stylianos Mandanas, Athanasios Papatheodorou, Polyzois Makras
Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. Calcified tissue international 108 (5) (2021)
Symeon Tournis, Maria P Yavropoulou, Stergios A Polyzos, Artemis Doulgeraki
Hypophosphatasia. Journal of clinical medicine 10 (23) (2021)
Victoria Potoupni, Maria Georgiadou, Eftychia Chatzigriva, Georgia Polychronidou, Erietta Markou, Christos Zapantis Gakis, Ioanna Filimidou, Myriam Karagianni, Dimitrios Anastasilakis, Kleo Evripidou, Argyro Ftergioti, Marianthi Togkaridou, Nikolaos Tsaftaridis, Apostolos Apostolopoulos, Stergios A Polyzos
Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. Journal of gastroenterology and hepatology 36 (11) (2021)
Jannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, Georgia Deretzi, Elisabeth Vardaka, Elpidoforos S Soteriades, Maria Tzitiridou-Hatzopoulou, Paraskevas Gkolfakis, Kyriaki Karafyllidou, Michael Doulberis
Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms 9 (11) (2021)
Michael Doulberis, Noah Thierry Pierre, Giulia Manzini, Apostolis Papaefthymiou, Jannis Kountouras, Jolanta Klukowska-Roetzler, Stergios A Polyzos, Simone Srivastava, Aristomenis K Exadaktylos, Jürg Knuchel, Thomas Kuntzen, David S Srivastava
Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. Microorganisms 9 (7) (2021)
Jannis Kountouras, Apostolis Papaefthymiou, Stergios A Polyzos, Michael Doulberis
A potential impact of Helicobacter pylori-related sarcopenia on severity of portal hypertension. Liver international : official journal of the International Association for the Study of the Liver 41 (5) (2021)
Jannis Kountouras, Michael Doulberis, Apostolis Papaefthymiou, Stergios A Polyzos
Impact of Helicobacter pylori-linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk. Liver international : official journal of the International Association for the Study of the Liver 40 (8) (2020)
Apostolis Papaefthymiou, Michael Doulberis, Stergios A Polyzos, Panagiotis Katsinelos, Jannis Kountouras
Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma. Alimentary pharmacology & therapeutics 51 (11) (2020)
Michael Doulberis, Apostolis Papaefthymiou, David S Srivastava, Aristomenis K Exadaktylos, Panagiotis Katsinelos, Jannis Kountouras, Stergios A Polyzos
Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection. International journal of clinical practice 75 (4) (2020)
Athanasios D Anastasilakis, Stergios A Polyzos, Maria P Yavropoulou, Polyzois Makras
Combination and sequential treatment in women with postmenopausal osteoporosis. Expert opinion on pharmacotherapy 21 (4) (2020)
Stergios A Polyzos, Gerhard Hawa, Teresa Jungwirth, Zacharoula Karabouta, Jannis Kountouras
Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. Hormones (Athens, Greece) 18 (4) (2019)
Jannis Kountouras, Apostolis Papaefthymiou, Michael Doulberis, Stergios A Polyzos
Influence of Helicobacter pylori-connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk. Liver international : official journal of the International Association for the Study of the Liver 40 (2) (2019)
Apostolis Papaefthymiou, Michael Doulberis, Panagiotis Katsinelos, Christos Liatsos, Stergios A Polyzos, Georgios Kotronis, Katerina Papanikolaou, Jannis Kountouras
Impact of nitric oxide's bidirectional role on glaucoma: focus on Helicobacter pylori-related nitrosative stress. Annals of the New York Academy of Sciences 1465 (1) (2019)
Stergios A Polyzos, Jannis Kountouras
CHAI and MACK-3 as noninvasive indices for nonalcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver 39 (8) (2019)
Athanasios D Anastasilakis, Socrates E Papapoulos, Stergios A Polyzos, Natasha M Appelman-Dijkstra, Polyzois Makras
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 34 (12) (2019)
Jannis Kountouras, Stergios A Polyzos, Michael Doulberis, Christos Stergiopoulos, Panagiotis Katsinelos
Comment on "Therapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Disease". Journal of immunology (Baltimore, Md. : 1950) 200 (9) (2019)
Stergios A Polyzos, Jannis Kountouras, Antonis Goulas, Leonidas Duntas
Selenium and selenoprotein P in nonalcoholic fatty liver disease. Hormones (Athens, Greece) 19 (1) (2019)
Stergios A Polyzos, Jannis Kountouras
Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. Helicobacter 24 (3) (2019)
Stergios A Polyzos, Jannis Kountouras, Sotiris Anastasiadis, Michael Doulberis, Panagiotis Katsinelos
Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach? Hepatology (Baltimore, Md.) 68 (1) (2018)
Stergios A Polyzos, Evangelos Terpos
Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine 62 (2) (2018)
Stergios A Polyzos, Jannis Kountouras, Athanasios D Anastasilakis, Polyzois Makras, Gerhard Hawa, Linda Sonnleitner, Albert Missbichler, Michael Doulberis, Panagiotis Katsinelos, Evangelos Terpos
Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones (Athens, Greece) 17 (4) (2018)
Stergios A Polyzos, Leonidas Duntas, Jens Bollerslev
The intriguing connections of leptin to hyperparathyroidism. Endocrine 57 (3) (2017)
Stergios A Polyzos, Jannis Kountouras, Christos S Mantzoros, Vaia Polymerou, Panagiotis Katsinelos
Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes, obesity & metabolism 19 (12) (2017)
Stergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, Polyzois Makras, Athanasios Papatheodorou, Panagiotis Kokkoris, Grigorios T Sakellariou, Evangelos Terpos
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. Journal of bone and mineral metabolism 34 (4) (2015)
Stergios A Polyzos, Athanasios D Anastasilakis
Periostin on the road to nonalcoholic fatty liver disease. Endocrine 51 (1) (2015)
Stergios A Polyzos, Konstantinos N Aronis, Jannis Kountouras, Dimitrios D Raptis, Maria F Vasiloglou, Christos S Mantzoros
Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59 (1) (2015)
Stergios A Polyzos, Stergios A Polyzos
Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity. Helicobacter 20 (6) (2015)

Stergios A Polyzos.css-eqlu8i{font-size:small;padding-left:4px;} (S A Polyzos, Jannis Kountouras)

Publication Activity (10 Years)

Top Topics

Top Venues

Stergios A Polyzos (S A Polyzos, Jannis Kountouras)